SecBot SecBot
SECBOTREPLAY Home › Report › TEVA

TEVA · Teva closed its acquisition of Emalex Biosciences for $700M upfront…

Teva Pharmaceutical Industries Ltd · PRESS-RELEASE filed Jun 10, 2026 at 12:03 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 10, 2026 at 12:03 ET

Teva closed its acquisition of Emalex Biosciences for $700M upfront plus up to $200M in milestones and sales-based royalties, adding ecopipam, a late-stage, first-in-class D1 antagonist for pediatric Tourette syndrome. NDA submission is expected in H2 2026, and Phase 3 data published in JAMA Neurology showed statistical significance on the primary endpoint.

  • $700 million upfront consideration paid at closing
  • Up to $200 million in additional commercial milestone payments plus net sales-based royalties
  • Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations
  • Phase 3 Tourette syndrome study met primary endpoint with statistical significance (p = 0.0084) and was published in JAMA Neurology

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access